Joseph R. Calabrese, M.D.
Director, Mood Disorders Program, University Hospitals Case Medical Center
Bipolar Disorder Research Chair & Professor of Psychiatry, CWRU School of Medicine
Dir., Bipolar Disorders Research Center
This week we are pleased to post the expert opinion of Joseph Calabrese, M.D. on the serious consequences of the proposed regulation to limit access to antidepressant, immunosuppressant and antipsychotic medications for recipients of Medicare Part D. Read the post and take action by participating in the conversation. This enables all of us to share these collective stories with our elected officials through e-mails, letters and in-person visits.
Why I’m Speaking Out Against the Proposed Medicare Part D Change —
And Why You Should, Too
Last month the Centers for Medicare and Medicaid Services (CMS) released a proposed rule that would initiate major changes to prescription drug plans under Medicare Part D. These changes would severely limit access to medications that are commonly used to treat serious mental illness and create serious challenges for people who have these mental health disorders.